Syndax Pharmaceuticals, Inc. Payments to Acquire Short-term Investments
Syndax Pharmaceuticals, Inc. (SNDX) reported Payments to Acquire Short-term Investments of $125.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $85.87M, a 6.37% decline year-over-year.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $39.39M, a 273.76% increase year-over-year.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $63.12M, a 83.23% decline year-over-year.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $30.44M, a 127.96% increase year-over-year.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2025 was $195.81M, a 64.85% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2024 was $557.05M, a 57.09% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2023 was $354.61M, a 28.41% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2022 was $495.35M, a 68.07% increase from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $125.26M 10-Q · filed 2026-08-04 | $188.38M derived: sum of 3 quarters · filed 2026-08-04 | $218.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $39.39M 10-Q · filed 2026-04-30 | $102.50M derived: sum of 2 quarters · filed 2026-04-30 | $132.94M derived: sum of 3 quarters · filed 2026-04-30 | $224.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $63.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $93.56M derived: sum of 2 quarters · filed 2026-02-26 | $185.27M derived: sum of 3 quarters · filed 2026-08-04 | $195.81M 10-K · filed 2026-02-26 |
| 2025-09-30 | $30.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $122.15M derived: sum of 2 quarters · filed 2026-08-04 | $132.69M 10-Q · filed 2025-11-03 | $509.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $91.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $102.25M 10-Q · filed 2026-08-04 | $478.56M derived: sum of 3 quarters · filed 2026-08-04 | $491.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $10.54M 10-Q · filed 2026-04-30 | $386.85M derived: sum of 2 quarters · filed 2026-04-30 | $400.20M derived: sum of 3 quarters · filed 2026-04-30 | $400.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $376.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $389.67M derived: sum of 2 quarters · filed 2026-02-26 | $389.67M derived: sum of 3 quarters · filed 2026-02-26 | $557.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $13.35M derived: sum of 2 quarters · filed 2025-11-03 | $180.74M 10-Q · filed 2025-11-03 | $310.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $167.38M 10-Q · filed 2025-08-04 | $296.68M derived: sum of 3 quarters · filed 2026-02-26 | $379.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $167.38M 10-Q · filed 2025-05-05 | $296.68M derived: sum of 2 quarters · filed 2026-02-26 | $379.40M derived: sum of 3 quarters · filed 2026-02-26 | $460.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $129.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $212.01M derived: sum of 2 quarters · filed 2026-02-26 | $293.02M derived: sum of 3 quarters · filed 2026-02-26 | $354.61M 10-K · filed 2026-02-26 |
| 2023-09-30 | $82.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $163.73M derived: sum of 2 quarters · filed 2024-11-05 | $225.32M 10-Q · filed 2024-11-05 | $476.19M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $81.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $142.59M 10-Q · filed 2024-08-01 | $393.47M derived: sum of 3 quarters · filed 2025-03-03 | $473.31M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $61.59M 10-Q · filed 2024-05-08 | $312.46M derived: sum of 2 quarters · filed 2025-03-03 | $392.30M derived: sum of 3 quarters · filed 2025-03-03 | $514.66M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $250.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $330.71M derived: sum of 2 quarters · filed 2025-03-03 | $453.08M derived: sum of 3 quarters · filed 2025-03-03 | $495.35M 10-K · filed 2025-03-03 |
| 2022-09-30 | $79.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $202.20M derived: sum of 2 quarters · filed 2023-11-02 | $244.47M 10-Q · filed 2023-11-02 | $349.69M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $122.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $164.63M 10-Q · filed 2023-08-03 | $269.86M derived: sum of 3 quarters · filed 2024-02-27 | $332.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $42.27M 10-Q · filed 2023-05-08 | $147.49M derived: sum of 2 quarters · filed 2024-02-27 | $210.44M derived: sum of 3 quarters · filed 2024-02-27 | $270.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $105.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $168.17M derived: sum of 2 quarters · filed 2024-02-27 | $227.99M derived: sum of 3 quarters · filed 2024-02-27 | $294.72M 10-K · filed 2024-02-27 |
| 2021-09-30 | $62.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $122.76M derived: sum of 2 quarters · filed 2022-11-03 | $189.49M 10-Q · filed 2022-11-03 | $318.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $59.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $126.55M 10-Q · filed 2022-08-08 | $255.13M derived: sum of 3 quarters · filed 2023-02-28 | $274.36M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $66.73M 10-Q · filed 2022-05-09 | $195.31M derived: sum of 2 quarters · filed 2023-02-28 | $214.54M derived: sum of 3 quarters · filed 2023-02-28 | $310.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $128.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $147.81M derived: sum of 2 quarters · filed 2023-02-28 | $244.00M derived: sum of 3 quarters · filed 2023-02-28 | $278.94M 10-K · filed 2023-02-28 |
| 2020-09-30 | $19.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $115.41M derived: sum of 2 quarters · filed 2021-11-15 | $150.35M 10-Q · filed 2021-11-15 | $185.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $96.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $131.13M 10-Q · filed 2021-08-09 | $166.25M derived: sum of 3 quarters · filed 2022-03-01 | $175.25M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $34.94M 10-Q · filed 2021-05-11 | $70.06M derived: sum of 2 quarters · filed 2022-03-01 | $79.06M derived: sum of 3 quarters · filed 2022-03-01 | $118.33M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $35.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $44.12M derived: sum of 2 quarters · filed 2022-03-01 | $83.39M derived: sum of 3 quarters · filed 2022-03-01 | $104.02M 10-K · filed 2022-03-01 |
| 2019-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $48.26M derived: sum of 2 quarters · filed 2020-11-05 | $68.89M 10-Q · filed 2020-11-05 | $87.59M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $39.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $59.89M 10-Q · filed 2020-08-06 | $78.60M derived: sum of 3 quarters · filed 2021-03-12 | $104.59M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $20.63M 10-Q · filed 2020-05-07 | $39.33M derived: sum of 2 quarters · filed 2021-03-12 | $65.32M derived: sum of 3 quarters · filed 2021-03-12 | $87.79M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $18.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $44.70M derived: sum of 2 quarters · filed 2021-03-12 | $67.16M derived: sum of 3 quarters · filed 2021-03-12 | $78.84M 10-K · filed 2021-03-12 |
| 2018-09-30 | $25.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $48.46M derived: sum of 2 quarters · filed 2019-11-07 | $60.14M 10-Q · filed 2019-11-07 | $99.39M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $22.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $34.15M 10-Q · filed 2019-08-07 | $73.40M derived: sum of 3 quarters · filed 2020-03-05 | $98.42M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $11.68M 10-Q · filed 2019-05-08 | $50.93M derived: sum of 2 quarters · filed 2020-03-05 | $75.96M derived: sum of 3 quarters · filed 2020-03-05 | $149.87M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $39.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $64.27M derived: sum of 2 quarters · filed 2020-03-05 | $138.18M derived: sum of 3 quarters · filed 2020-03-05 | $152.26M 10-K · filed 2020-03-05 |
| 2017-09-30 | $25.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $98.93M derived: sum of 2 quarters · filed 2018-11-05 | $113.01M 10-Q · filed 2018-11-05 | $139.58M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $73.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $87.99M 10-Q · filed 2018-08-08 | $114.56M derived: sum of 3 quarters · filed 2019-03-07 | $136.38M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $14.08M 10-Q · filed 2018-05-09 | $40.65M derived: sum of 2 quarters · filed 2019-03-07 | $62.47M derived: sum of 3 quarters · filed 2019-03-07 | $93.54M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $26.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $48.39M derived: sum of 2 quarters · filed 2019-03-07 | $79.46M derived: sum of 3 quarters · filed 2019-03-07 | $158.32M 10-K · filed 2019-03-07 |
| 2016-09-30 | $21.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $52.89M derived: sum of 2 quarters · filed 2017-11-08 | $131.75M 10-Q · filed 2017-11-08 | $165.04M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $31.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $109.93M 10-Q · filed 2017-08-10 | $143.22M derived: sum of 3 quarters · filed 2018-03-08 | $169.90M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $78.86M 10-Q · filed 2017-05-09 | $112.15M derived: sum of 2 quarters · filed 2018-03-08 | $138.83M derived: sum of 3 quarters · filed 2018-03-08 | $159.31M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $33.29M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $59.97M derived: sum of 2 quarters · filed 2018-03-08 | $80.44M derived: sum of 3 quarters · filed 2018-03-08 | $102.01M 10-K · filed 2018-03-08 |
| 2015-09-30 | $26.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $47.16M derived: sum of 2 quarters · filed 2016-11-14 | $68.72M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $20.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $42.04M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $21.56M 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $3.39M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |